The University of Chemistry and Technology, Prague (UCT Prague) was founded in 1952 as far more than just an institute of higher education, but as a solution to our worlds most pressing challenges as well. Its students and graduates are proof.

Doors didnt just magically open for Thea Baum when she graduated from the university in 2015. It was her qualifications prestige that made the process ever-so-seamless. Recruiters and decision-makers were immediately impressed.

It was relatively easy to find a job after my graduation, she attests. I found a number of job opportunities and I went to a couple of interviews enabling me to make a decision based on the best fitting employment opportunity.

She chose PharmInvent, where she would be able to serve as a Scientific and Regulatory Specialist in the Pharmaceuticals Regulatory Affairs sector and apply all the knowledge and skills she gained as a Masters in Biotechnology student at UCT Prague.

My current position in PharmInvent is strongly related to my field of study at UCT Prague, she explains. The education acquired at the university enabled me to have a good grasp of the technologies currently in use in the biotechnology industry. I am able to understand current EU legislation related to the food, chemical or microbiological industries which helps me consider the regulatory requirements that need to be addressed in pharmaceuticals.

UCT Prague is one of the countrys largest educational and research institutions. Source: University of Chemistry and Technology, Prague

Such confidence is typical of budding changemakers who choose UCT Prague. The theme of sustainability persists across its Faculty of Chemical Technology, Faculty of Environmental Technology, Faculty of Food and Biochemical Technology, Faculty of Chemical Engineering, the Department of Physical Education and Sport, Department of Education and Human Sciences, Department of Languages, and the Department of Economics and Management (also known as the UCT School of Business).

Within them, students can choose from a wide array of bachelors, masters and PhD programmes taught in English. With a student to faculty ratio of 20:1, classes are productively intimate. Hence, curricula are hands-on and ample guidance awaits in state-of-the-art, facility-filled spaces. Essentially, everything one could need to gear up for a future of change-making is ready and waiting. Pathways abound for such outcomes.

Take the MSc in Sustainability and Environmental Engineering, for instance. This programme provides learners with expert knowledge of environmental chemistry, microbiology, hydrobiology, water and atmosphere technologies, decontamination technologies, and waste handling technologies all of which are crucial for tomorrows green heroes.

Its interdisciplinary nature ensures students are comprehensively trained to leverage water technologies and air protection technologies. Additional lessons shed light on industrial toxicology, ecotoxicology, environmental analysis, decontamination technologies, and environmentally-oriented legislation. All of the above develops graduates capable of thriving in the fields of process engineering, research and development, design, as well as production control, among many others.

UCT Prague boasts many state-of-the-art laboratories open to all students. Source: University of Chemistry and Technology, Prague

The MSc in Biotechnology and Food Science is equally impactful a programme designed to produce experts with high-level knowledge in biotechnology, bioengineering and food science, with an emphasis on food quality and safety.

It enhances general knowledge gained at the undergraduate level in biochemistry, organic and physical chemistry, biology, microbiology, food technology and analysis, and the fundamentals of biotechnology and bioengineering. Upon successful completion, graduates are primed to assume high-level positions in biotechnological companies, food production plants, organisations oriented to agricultural commodities, the health care sector or pharmaceutical companies.

Business-focused aspirants easily find their place at UCT Prague as well. Its School of Business houses a Sectoral Management Masters programme that prepares professionals for mid- and top-level management positions in industry, industrial policy, innovation policy, commercial policy and finance. At the same time, it lays a solid foundation for academic advancement or research careers through a PhD. The programme offers two majors: Innovation Project Management and Chemical Industry.

The first option is ideal for students keen on gaining proficiency in Financial Management, Project Management, Process Management or Logistics and Supply Chain Management. Meanwhile, the latter is aimed at those seeking more technical expertise particularly relevant for positions in the chemical, food-processing, fuels, rubber or environmental protection industries.

Anything is possible at a university where graduates have gone as far as developing vaccines in the Czech Republic. To find out how you could make a similar impact, click here to learn more about UCT Prague.

Follow the University of Chemistry and Technology, Prague on Facebook, Instagram, Twitter, and YouTube.

The rest is here:
Global changemakers: University of Chemistry and Technology, Prague - Study International News

Research at Harvards School of Engineering and Applied Sciences spans interdisciplinary academic fields and relies on collaboration with organizations beyond the University including for-profit partners.

While some faculty members and students highlight the benefits of corporate partnerships, others caution working with for-profit entities requires balancing ethical risks and educational rewards.

Ellie Carlough, who heads SEASs collaboration with the private sector, said her position as director of industry partnerships was established by SEAS Dean Francis J. Doyle III, who she said has stressed the value of long-term industry partnerships.

The emphasis of the partnership building is not on raising funds or extra sponsored research funding, although that is certainly an element, she said. The main goals were to build partnerships to support students and faculty.

Carlough said corporate partnerships provide internship and employment opportunities to students, while also exposing them to real-world applications of science and engineering.

She lauded Engineering Sciences 96: Engineering Problem Solving and Design Project as an experiential class that allows students to benefit from the schools corporate partnerships. Students in the course are commissioned to solve a challenge faced by an industry sponsor and receive mentorship from these outside experts.

Samir Mitragotri, a bioengineering professor who taught ES96 in the fall, said he has found SEASs collaboration with industry partners to be educationally rewarding.

It not only provides benefits in the research direction, but also it provides a good educational component to the students, Mitragotri said. A lot of our students, when they graduate, go on to industry, and for them to really have this context as a part of their education I think is quite helpful.

Engineering student Yasmin Omri 24 similarly praised CS 148: Design of VLSI Circuits and Systems. Her professor obtained a partnership with a semiconductor fabrication plant to tape-out the computer chips that she and her peers were designing. She called this partnership motivating for her work.

Had they not been able to secure a partnership with that corporation, I think the learning would probably be more theoretical, she said. Having the actual implementation happen is dependent on having corporate partnerships.

But Mitragotri acknowledged a difference between the interests of scholars and corporations, who must answer to stakeholders.

There is an immediate sense of practicality and utility in industrial engineering, Mitragotri said, whereas in academia, researchers enjoy the luxury of asking very open, futuristic questions.

SEAS professor James H. Waldo said he has previously encountered industry partners who have attempted to dictate what he would report in his research, but he stood his ground.

Making sure you dont fall into the Here, Ive got some money. Go do something for me trap is important, Waldo added.

According to Waldo, SEAS has strong ethical guidelines in place to avoid conflicts of interest, but theres no way really to enforce all ethical questions. He added that researchers have discretion over the private companies with whom they partner.

This is not something for which there is a hard and fast rule, he said. This is something where we have to rely on the good judgment of the academics involved, of the industry involved.

According to University spokesperson Jason A. Newton, Harvards Office of Technology Department puts in place policies to preserve the integrity of research partnerships with corporations. All research agreements developed by OTD set reasonable limits on rights granted to corporate partners and refuse to promise any specific research results, Newton wrote in an email.

The research and any resulting IP are provided to the company on an as is basis, he wrote.

Engineers Without Borders, a student organization, also works closely with corporations, which offer technical support and help further the clubs long-term projects.

Having these corporations and business professionals in our network really helps us bring to reality any sort of ideas that we have, and really learn from them, said Omri, co-president of EWB.

Omri said she hopes the school investigates the social and environmental responsibilities of potential industry sponsors before entering into partnerships.

My hope is that theyre established on ethical grounds, she said.

Staff writer Felicia He can be reached at felicia.he@thecrimson.com.

Staff writer James R. Jolin can be reached at james.jolin@thecrimson.com.

Go here to see the original:
Faculty and Students Weigh the Risks and Rewards of SEAS' Corporate Partnerships | News - Harvard Crimson

Concurrent with the commitment to endow the new center, Merkin and the Merkin Family Foundation have provided funds to renovate the eighth floor of Caltech Hall. The reconfigured space, scheduled to open in early 2023, will provide a home for the center as well as a base of operations for the American Institute of Mathematics (AIM), which is relocating from its current headquarters in San Jose, California, to Caltech.

Sergei G. Gukov, the John D. MacArthur Professor of Theoretical Physics and Mathematics, has been named director of the Merkin Center. A member of the Caltech faculty since 2005, Gukov is known for important concepts relevant to string theory, quantum field theory, and pure mathematics.

"Caltech has cultivated extraordinary scholars who think deeply about landmark problems in pure mathematics and collaborate across disciplines," says Fiona A. Harrison, the Harold A. Rosen Professor of Physics and holder of the Kent and Joyce Kresa Leadership Chair in the Division of Physics, Mathematics and Astronomy. "The Institute is also home to a diverse community of researchers who push the frontiers of applied mathematics in areas as wide-ranging as algorithmic economics, computational biology, robotics and autonomous control, and quantum information and computing.

"The Merkin Center for Pure and Applied Mathematics will broaden and deepen the impact of the mathematical sciences across campus."

A Passion for Mathematics

As a physician and health care executive, Merkin has devoted much of his philanthropy to supporting basic science and its translation into medical treatments and cures. His love of mathematics, his undergraduate major, has been another significant thread throughout his engagement with Caltech.

Merkin previously endowed two mathematics professorships at the Institute. These positions, together with the Richard N. Merkin Distinguished Visiting Professorship in Artificial Intelligence, will be woven into the Merkin Center.

Jaka Cvitani, the Richard N. Merkin Professor of Mathematical Finance and director of The Ronald and Maxine Linde Institute of Economic and Management Sciences, is an expert in financial economics who focuses on the intersection between computer science and economics. Nikolai Makarov, the Richard Merkin Distinguished Professor of Mathematics, has worked extensively in complex analysis, which investigates functions of complex variables. This field is fundamental to many branches of mathematics and has applications in the natural sciences and engineering.

Both Cvitani and Makarov will serve as advisers to the new Merkin Center for Pure and Applied Mathematics, together with Elena Mantovan, a professor of mathematics who focuses on arithmetic geometry and number theory.

Mathematics at Caltech

Although small, Caltech's pure mathematics program is expansive in terms of focus and impact. Mathematics scholars at the Institute work together and with colleagues across disciplines to untangle some of the most difficult problems in the field and have garnered high honors for pushing the frontiers of analysis, combinatorics, group theory, mathematical physics, and number theory. They have written texts that are considered foundational to the discipline, and the Institute relies on them to help impart the quantitative skills in which all Caltech graduates become well versed.

Investigators in the Institute's highly ranked Computing and Mathematical Sciences (CMS) department are active in applied mathematics, communication and networks, computer science, and control and systems. Like Caltech's mathematics faculty, CMS faculty are highly collaborative. They have built partnerships with colleagues in mathematics as well as in applied physics, bioengineering, biology, economics, electrical engineering, geology and planetary sciences, mechanical engineering, and physics.

Caltech is also home to a world-leading research center in quantum information and computation. Scholars affiliated with the Institute for Quantum Information and Matter (IQIM) explore the interplay of mathematics, computer science, and physics.

Mathematics is central to the work of faculty and students in numerous other areas across campus, in part due to the sheer amounts of data being collected. Among the researchers who stand to benefit from partnership with the Merkin Center are those working on models of neural processing and brain function, predictive modeling of health care diagnoses, election security, earthquake modeling, "smart" energy grids, and climate models to enable more accurate prediction of droughts, heat waves, and rainfall extremes.

Merkin's Previous Support of Caltech

A member of the Caltech Board of Trustees since 2007, Richard Merkin has supported a variety of initiatives across campus. His previous gifts have created the Heritage Research Institute for the Advancement of Medicine and Science at Caltech, founded in 2015 and renewed in 2018 and 2021, which provides cohorts of Caltech scientists and engineers with salary support and no-strings-attached research funds that free them to pursue high-risk, high-reward projects. Merkin also partnered with Caltech to launch the Richard N. Merkin Institute for Translational Research, which enables scientists and engineers to transform their breakthroughs into advances in human health. Additionally, beginning in 2021, the Richard N. Merkin Start-Up Scholars Grants have provided pre-arrival support to help incoming undergraduates from low-income backgrounds make a successful transition to campus life.

"Richard Merkin is a remarkable philanthropist, making possible fundamental discovery across a broad range of fields and encouraging intersections with the practical," says Caltech president Thomas F. Rosenbaum, the holder of the Sonja and William Davidow Presidential Chair and professor of physics. "Above all, Dick takes joy in making it possible for researchers to thrive, whether they be students, postdocs, or faculty members."

See the original post:
Caltech Launches Merkin Center for Pure and Applied Mathematics - Caltech

Dr. Shalini Prasad

Dr. Shalini Prasad, professor and head of bioengineering at The University of Texas at Dallas, was elected a fellow of the American Institute for Medical and Biological Engineering (AIMBE) for her pioneering contributions in developing sweat wearables for tracking and management of chronic diseases and for prognostic monitoring in pandemics.

The AIMBE College of Fellows is composed of the top 2% of medical and biological engineers in the country. Prasad was inducted at a March 25 virtual ceremony along with 153 colleagues who make up the newest class of fellows.

As a bioengineer, I have witnessed the practical demonstration of the whole being greater than the sum of its parts, said Prasad, who is also a Cecil H. and Ida Green Professor in Systems Biology Science in the Erik Jonsson School of Engineering and Computer Science. Every biomedical device technology that I have created comes together by integrating engineering and sciences, and the impact is monumental. It is fabulous to wake up every day as a bioengineer.

The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators and successful entrepreneurs comprise the College of Fellows. Fellows include clinicians, industry professionals, academics and scientists who have distinguished themselves through their contributions in research, industrial practice and/or education.

In addition to Prasad, other UTDallas faculty members who have been elected to the College of Fellows are Dr. Stuart Cogan, professor of bioengineering; Dr. Baowei Fei, professor of bioengineering and Cecil H. and Ida Green Chair in Systems Biology Science; Dr. Joseph Pancrazio, vice president for research and innovation and professor of bioengineering; Dr. Walter Voit BS05, MS06, associate professor of materials science and engineering and of mechanical engineering; and Dr. Jie Zheng, professor of chemistry and a Cecil H. and Ida Green Professor in Systems Biology Science.

Chen Chen

Chen Chen, a doctoral electrical engineering student at The University of Texas at Dallas, received a predoctoral achievement award from the Solid-State Circuits Society of the Institute of Electrical and Electronics Engineers (IEEE).

The award, which was presented in January, is given to about two dozen promising graduate students from around the world each year. Chen, who joined UT Dallas in 2018, works on developing more compact and energy-efficient power converters for electric vehicles and next-generation computing systems. Her research interests include power management integrated circuits; hybrid power converter topologies and methodologies; and zero-voltage-switching techniques.

Most recently, Chen presented her research at the IEEE International Solid-State Circuits Conference in February. She has been first author of studies in publications, including the IEEE Journal of Solid-State Circuits. In 2021, Chen received an outstanding student designer award from Analog Devices. Her research has been supported by Semiconductor Research Corp. and UT Dallas Texas Analog Center of Excellence.

As a UTD PhD student in the integrated circuit (IC) design research field, I am very honored and humbled to receive this prestigious award. I hope I can help as a role model for many UTD undergraduate and graduate students who are interested in the IC design research field, she said.

Chens advisors are Dr. Hoi Lee, professor of electrical and computer engineering, and Dr. Jin Liu, professor of electrical and computer engineering.

See the rest here:
Bioengineering Professor Elected to AIMBE College of Fellows - University of Texas at Dallas

The College of Engineering and Computer Science held its annual Research Day on March 25, with the following projects taking home awards in their respective categories.

Poster Competition

First place: Elizabeth Oguntade, PhD. student in Bioengineering.On-Demand Activation of Functional Protein Surface Patterns with Tunable Topography Suitable for Biomedical Applications. Advisor: Dr. James Henderson

Second place: Natalie Petryk, MS student in Bioengineering. Synthesis of Shape Memory Polymer Foams with Off-the-Shelf Components for Improved Commercialization. Advisor: Dr. Mary Beth Monroe

Third place: Alexander Hartwell, PhD student in Mechanical and Aerospace Engineering. Introduction of a Multilayered Cathode for Improved Internal Cathode Tubular Solid Oxide Fuel Cell Performance. Advisor: Dr. Jeongmin Ahn

Honorable Mention: Saif Khalil Elsayed, MS student in Civil Engineering.Modeling Self-Folding Hybrid SU-8 Skin for 3D Biosensing Microstructures. Advisor: Dr. Zhao Qin

Oral Presentation Competition

Communication and Security Session

First place: Kai Li, PhD student in Electrical/Computer Engineering. Detect and Mitigate Vulnerabilities in Ethereum Transaction Pool. Advisor: Dr. Yuzhe Tang

Second place: Xinyi Zhou, PhD student in Computer/Information Science. This is Fake! Shared it by Mistake: Assessing the Intent of Fake News Spreaders. Advisor: Dr. Reza Zafarani

Health and Well-Being Session

First place: Yousr Dhaouadi, PhD student in Chemical Engineering. Forming Bacterial Persisters with Light. Advisor: Dr. Dacheng Ren

Second place: Henry Beaman, PhD student in Bioengineering. Gas-Blown Super Porous Hydrogels with Rapid Gelling and High Cell Viability for Cell Encapsulation. Advisor: Dr. Mary Beth Monroe

Energy, Environment and Smart Materials Session

First place: Durgesh Ranjan, PhD student in Mechanical and Aerospace Engineering. Porous nanochannel wicks based solar vapor generation device. Advisor: Dr. Shalabh Maroo

Second place: Alexander Johnson, PhD student in Civil Engineering. Estimating Dry Deposition of Atmospheric Particles by Rain Washoff from Urban Surfaces. Advisor: Dr. Cliff Davidson

Sensors, Robotics and Smart Systems Session

First place: Lin Zhang, PhD student in Computer/Information Science. Adaptive Sensor Attack Detection for Cyber-Physical Systems. Advisor: Dr. Fanxin Kong

Second place: Zixin Jiang, PhD student in Mechanical and Aerospace Engineering, Short-term occupancy prediction driven intelligent HVAC control. Advisor: Dr. Bing Dong

Follow this link:
2022 Engineering and Computer Science Research Day Awards - Syracuse University News

Drew Endy, PhD, a Stanford bioengineer, is the kind of brilliant that makes your head spin. His ideas come at a mile a minute, each one a potential mini revolution of standard biology, and his excitement for his work is palpable. But, to me, the best part about Endy is his drive to see a mega-mission through: to use bioengineering to change the world for the better, making contentious efforts to innovate with an eye toward solving social, humanitarian and environmental challenges.

In one of my latest Stanford Medicine magazine stories, "How synthetic biology could save us," I speak to Endy about his lofty vision and the research he's conducting to see it through.

If you ask Endy, synthetic biology is a field that aims to "make the making of things" easier. It's a type of science that expands beyond the natural world, creating tools and techniques to support the development of new biology-based innovations -- like new forms of medicine, or an altered crop that can fight pests on its own.

"We tend to think of biology as something that happens to us," Endy said in the story. "But more and more, we are happening to biology. We're in an era, scientifically, where we can express our intentions into the very kernel of life to allow for possibilities that are simply never going to exist otherwise."

One of Endy's big projects is something he calls "the cleanome," a concept rooted in genetics, but with a twist: In a cleanome, all of an organism's non-crucial genetic elements are removed. (Every living thing contains fundamental genes that support its life, in addition to stretches of DNA that are, essentially, garbage.) The goal is to remove genetic fluff, leaving only the core components that allow an organism to survive.

As Endy said in the story:

If you want to build an organism, you want to definitively know what you're working with, and right now part of what bioengineers are working with is ambiguity."

What bioengineering really needs, according to Endy, is certainty as to which genes are needed for a particular organism to survive along with what each gene is doing. ... Establishing a cleanome for key organisms would allow bioengineers to build and create with more certainty and safety, he said.

Endy and the researchers in his lab have other big ideas percolating too, one of which he's dubbed a "fail-safe" -- basically a built-in self destruct button for an engineered organism. Say, for instance, a scientist creates a type of cancer-fighting cell that runs around the body and gobbles up tumor cells. If that cell started to evolve new cell-gobbling abilities, that would be dangerous. A fail-safe construct built into the cell would notice such a change and kill the rogue cell before it kills its healthy neighbors.

During our interviews, I reflected on the enormity of his proposal: A civilization that not only coexists with bioengineering but also depends on it, harnesses it, continually develops it -- even loves it.

"You'd almost have to be some sort of benevolent dictator to truly see it through," I'd joked to him. He sees it a little differently. "Perhaps more like reluctant philosopher king."

Image by David Plunkert

Link:
Saving the world with synthetic biology - Scope - Scope

USAID animal disease surveillance work in Asia. Credit: Richard Nyberg / USAID. Credit: CC BY-NC 2.0.

In 2011, three top US government scientists penned an opinion piece in The Washington Post arguing why research modifying highly pathogenic avian influenza (H5N1) was a worthy undertaking. At the time, the National Institutes of Health (NIH) was facing blowback over having funded experiments that modified the virus to be transmissible among ferrets. The scientists argued that eliciting potentially dangerous mutations in the virus was necessary to protect humanity, should those mutations evolve naturally.

We cannot predict whether or not something will arise naturally, nor when or where it might appear. Given these uncertainties, important information and insights can come from generating a potentially dangerous virus in the laboratory, wrote Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases, Francis Collins, the head of NIH, and Gary Nabel, then a top official at Faucis institute.

Amid the controversy generated by this influenza research, the US government implemented a pause on federal funding in 2014 for selected research reasonably anticipated to increase transmissibility or pathogenicity of influenza, SARS, and MERS viruses. These were experiments that fell within a subset of scientific study called gain-of-function research. In 2017, the government lifted the pause and put in place a requirement that the US Department of Health and Human Services conduct a risk-benefit assessment on research that could confer these attributes to potential pandemic pathogens.

The federal government continues to fund such experimentation, but, as scientists, media, and online sleuths have delved into the origins of COVID-19, they have revealed weaknesses in past and current government oversight of projects modifying viruses. The revelations have underscored the degree to which gain-of-function research in the name of predicting pandemics is an idea that doesnt seem to fade.

US-funded coronavirus bioengineering. In 2018, EcoHealth Alliance, a US-based nonprofit research organization, submitted a grant proposal to the Defense Advanced Research Projects Agency (DARPA) called DEFUSE: Defusing the Threat of Bat-borne Coronaviruses asking for over $14 million for a three-and-a-half year project to, as the name suggests, prevent a bat coronavirus from spilling over into people and seeding an outbreak. The team would study viral evolution and spillover risk[s] of SARS-related bat coronaviruses by collecting viruses from caves in Yunnan, China and doing experiments that included testing hybrid, lab-created bat coronaviruses on mice engineered to have human receptors.

One eye popping segment in the 2018 EcoHealth proposal to DARPA dealt with finding so-called furin cleavage sites. In SARS-CoV-2, the virus that causes COVID-19, a furin cleavage site allows its spike protein to be cut by the furin enzyme present in human airway tissues, making the virus better able to infect cells than others without the feature. The furin cleavage site represents a crucial difference between the COVID-19 virus and its relatives, including SARS-CoV, the virus responsible for the 2003 outbreak of that respiratory disease.

The process by which viruses hijack the cellular machinery of their hosts to reproduce themselves is sloppy, and the viruses that a cell produces arent always identical to the ones that infected the cell to begin with. This sloppiness helps the virus to evolve and adapt to new hostssuch as us. The furin cleavage site in SARS-CoV-2 could have evolved in this way.

Some proponents of the idea that the pandemic began with a lab accident in Wuhan, however, wonder whether the furin cleavage sites presence in the COVID-19 virus is simply a mark of natural viral evolutionan artifact of sloppy viral reproductionor rather is something else entirely: a sign of human bioengineering.

DARPA did not approve EcoHealths 2018 proposal, and its unknown whether the project received other funding. But the EcoHealth proposal, like another of the organizations collaborations with the Wuhan Institute of Virology that did get government funding, show the enduring interest scientists have in modifying viruses in the name of predicting pandemic pathogens. (NIH officials have denied that EcoHealths NIH-funded research is gain of function research, although NIH documents show that the organization failed to adhere to terms related to enhanced viral growth in its hybrid bat coronavirus studies. There is significant debate on what the definition of a dangerous gain-of-function experiment is.)

Predicting pandemics through gain-of-function research. An overarching goal of EcoHealths workas documented in the DARPA proposal and in other projectswas to learn which viruses were poised to spill over, in other words, to predict pandemics. Predicting how and when the next pandemic could arise is important, but tampering with viruses to do so is the wrong way to go about it. Predicting pandemics isnt like predicting the weather.

Weather prediction is a purely observational exercise. We have satellites and other tools to track weather to predict hurricanes. The forecast process begins with observations. Scientists use this data to develop hurricane forecast models. Geophysical fluid dynamics are well understood, based on the laws of physics (i.e. density, flow velocity, pressure, and temperature) enabling scientists to develop atmospheric and climate models.

Scientists do not experiment on clouds to see if they can cause hurricanes.

In 2004, the National Academy of Sciences published its seminal report, Biotechnology Research in an Age of Terrorism. It listed seven experiments of concern that should not be done.

Bioengineering SARS-related coronaviruses in ways that could increase efficient infection of human cells and that increase viral load, pathogenicity, and lethality in mice genetically engineered to have respiratory cells with human features, i.e., humanized mice, as NIH documents show was done by EcoHealth Alliance and its Wuhan partners, would conceivably implicate points 3, 4, and 5 of the 2004 report. Whether the Wuhan experimentation was gain of function is a matter of debate, but some scientists disagree with NIHs assessment that it wasnt.

Ideally, Congress should hold a hearing to debate what kind of research should not be done and do more to investigate the origins of the pandemic. Certainly, there have been calls to do so.

There are other less risky ways of preventing pandemics than conducting gain-of-function research on pathogens. Many pathogens capable of causing human outbreaks originate in animals, and surveillance of wild and domestic animals for signs of illness makes sense. This is the One Health approach. With One Health, the goal is to prevent the spread of deadly zoonotic microbes into humans through improved communication and collaboration between human and veterinary medicine.

Preventing pandemics through rapid identification and response is an important goal; the One Health approach that emphasizes animal and human health and disease surveillance is the key to doing this, not risky gain-of-function research.

Authors note: Many thanks to Richard Ebright, Board of Governors Professor of Chemistry and Chemical Biology, Waksman Institute, Rutgers University for his invaluable comments and links to technical references.

See the original post here:
Creating dangerous viruses in the lab is a bad way to guard against future pandemics - Bulletin of the Atomic Scientists

PUNE: The MIT School of Bioengineering Sciences & Research, MIT ADT University, Pune, has organized the fourth international conference on Recent Trends in Bioengineering (ICRTB 2021) on February 12 and 13 through virtual mode, a statement issued by the university said. The conference will be inaugurated by chief guest Aliasger K. Salem, Bighley Chair of the Pharmaceutical Sciences University of Iowa, USA, Mangesh Karad, Executive President and Vice-Chancellor, and Vinayak Ghaisas, Director of the BIO Engineering Institute and convenor of the conference.The conference theme areas include nanobiotechnology, synthetic biology, tissue engineering, environmental biotechnology, wearables & diagnostics, assistive devices, biomedical robotics, medical image processing, nanoinformatics, immunoinformatics, drug design, AI, and Big data in biology and Biomaterials.The two-day conference will include talks by eminent keynote speakers such as Dr. Karl Bohringer, Professor at University of Washington USA, Dr. Jeremy Simpson, Professor, University College Dublin, Ireland, Dr. Anurag Agrawal, Director at CSIR-IGIB India, among many others.More than 100 abstracts have been received for oral and poster presentations from all over India and abroad. The organizers have collaborated with the Springer Journal of Medical and Biological Engineering for publishing selected high-quality research papers that will be presented at the conference. An industry expo is also organized with participation from various bioengineering companies displaying their innovative products and solutions.

Continue reading here:
International conference on trends in bioengineering - Times of India

Stroke is the leading cause of mortality and disability among adults in China and is associated with high incidence, disability, mortality and recurrence rates, as well as high financial costs.Among the types of stroke, Acute Ischemic Stroke ("AIS") accounts for approximately 70%[1] of stroke cases in China and has been associated with a 10% mortality rate within the first 90 days as well as disability rates in more than a third of patients.The National Health Commission ("NHC")'s Healthy China Action (2019-2030) aims to lower mortality rates from cardiovascular and neurovascular diseases to the region of 20%[2], and more recently, the Bureau of Medical Administration under China's National Health Commission has targeted to increase the rates of reperfusion therapy for acute cerebral infarctions[3].

Direct aspiration for AIS can achieve efficacious recanalization of neurovascular arteries, achieve timely reperfusion and improve prognosis, and has been globally recommended as a treatment approach.China's leading physician in the field, Dr. Miao Zhongrong, Professor of Interventional Neuroradiology, Neurosurgery, and Neurology and Head of the Department of Interventional Neuroradiology at Beijing Tiantan Hospital (Capital Medical University), commented, "Afentta has demonstrated shorter procedure times, higher recanalization rates, lower disability rates and lower incidence of arterial dissection, presenting a more efficacious, faster and safer treatment option in interventional thrombectomy."

The Afentta intracranial thrombectomy aspiration catheter is the flagship product developed by HeMo Bioengineering (China) Ltd and has achieved the milestone of being China's first domestically-produced aspiration catheter system. Dr. Jack Wang, HeMo's Founder and Chief Technology Officer, commented, "HeMo Bioengineering is committed to bringing together 'smart' resources to serve China's needs in the neurovascular interventional space.With our professional management team of industry veterans and our diversified and global research and education resources, we are well-positioned to continue delivering world-leading, reliable and innovative medical devices."

HeMo has entered into technology partnerships with U.S.-based Imperative Care, Inc. and Tsinghua University's Department of Chemical Engineering, and has embarked on clinical trial collaborations with Beijing Tiantan Hospital (Capital Medical University).HeMo has also obtained patent protections for the proprietary technologies associated with its aspiration catheter system.Moving forward, HeMo is committed to accelerating the rapid development of China and APAC markets' interventional domain.

About HeMo Bioengineering Ltd:

Headquartered in Singapore, HeMo Bioengineering Ltd ("HeMo") is a fast-growing medical device company focused on the R&D and production of innovative medical devices for treating stroke patients.HeMo's current suite of neuro interventional products covers ischemic stroke, haemorrhagic stroke and neuro access. HeMo also has a strong presence in China, with manufacturing facilities in Weihai, Shandong and sales offices in Beijing and Shanghai. With a robust and diversified pipeline of other vascular intervention products under development, HeMo is well positioned to become a leading, global platform company in vascular intervention.

Visit HeMo at http://www.hemocorp.com.

For enquiries, please e-mail [emailprotected].

SOURCE HeMo Bioengineering Ltd

Home

Follow this link:
Singapore-based HeMo Bioengineering Receives China's NMPA Approval for flagship Afentta(TM) Aspiration Catheter - PRNewswire

Early on in the pandemic, Lee Makowski read an article about the condition of peoples bodies after dying of COVID-19, and he was shocked by what he learnedthere was something very wrong with the patients blood.

The autopsy reports revealed COVID-19 patients were suffering from huge amounts of thick, coagulated blood, and dysfunctional blood vessels were tearing through body tissue instead of repairing ithighly uncommon side effects of respiratory diseases.

Lee Makowski, chair of the bioengineering department at Northeastern. Photo by Matthew Modoono/Northeastern University

The postmortem evidence plus his own experience with something called COVID toesan odd side effect of the disease that causes heightened blood vessel formation in the toes, turning them bright redled Makowski to speculate that something about the virus might be causing abnormal blood-related complications.

One of the most perplexing and devastating effects of this disease is the scenario where three or four weeks after being hospitalized with pneumonia, people under the age of 50 are back home, they feel fine, and then all of a sudden they have a stroke and die, says Makowski, professor and chair of the bioengineering department at Northeastern.

Makowski, who recently published his hypothesis in the journal Viruses, believes the spike protein found on the surface of the virus might mimic proteins that regulate blood vessels and control the formation of blood clots, which could explain many of the non-respiratory complications of COVID-19.

The spike protein is an arm-like apparatus that the virus uses to attach to and enter healthy cells. At the tip of the spike protein rests a string of three amino acids called RGD. This structure is known for connecting cells to each other in the body.

Researchers dont know yet whether RGD is the culprit for COVID-19s blood-related complications, but they do know that RGD can contribute to the formation of blood clots and the growth of new blood vessels when it interacts with cell receptors called integrins.

Other proteins that have RGD are known to cause complications. Our theory is that RGD is making it easier for the virus to bind to things that could cause these blood complications, says William Olson-Sidford, a third-year bioengineering student and co-author of the paper who worked on this project as a co-op last fall.

Right now, researchers know that the viruss spike protein binds to cell receptors called ACE2. ACE2 is found in many cell types including in the lungs, heart, blood vessels, kidneys, liver, and gastrointestinal tract.

But our theory is that because [the virus] has an RGD, it may also be more likely to bind to other cells in the body that people arent thinking about, Olson-Sidford says.

Makowski hypothesizes that dysregulated blood vessel growthwhich can disrupt lung tissueis triggered by an increase of RGD during infection.

As for COVID-19-related kidney failure, its hard to know whether its caused by direct damage to the tissue by viral invasion or indirect damage through coagulation and blocked arteries, Makowski says. But either way, a faulty connection between RGD and integrin could be the culprit.

Recognizing that coagulation is a major problem has greatly improved the survival rate of people who are severely sick with COVID-19, Makowski says. Now if you end up in the ICU, you almost always get an anticoagulant, and that saves a lot of lives.

Uncovering the cause of that coagulation is the next step. Makowski hopes his hypothesis will spur other researchers to investigate further.

For media inquiries, please contact Shannon Nargi at s.nargi@northeastern.edu or 617-373-5718.

Read more here:
COVID-19 can affect the blood. Its spike protein may be the culprit. - News@Northeastern

A research team led by Samir Mitragotri, the Hiller Professor of Bioengineering and Hansjorg Wyss Professor of Biologically Inspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and Rahmi Oklu, of the Mayo Clinic, report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab. This discovery could solve a problem that has long plagued drug delivery to tumors and provide new hope to patients with liver cancer awaiting a liver transplant.

The preclinical study results are published in Science Translational Medicine.

Uniform drug delivery to tumors is often riddled with challenges. Higher drug doses are often used to encourage drug delivery into the tumor, and these higher doses could lead to significant toxicity.

"If the drug cannot penetrate the tumor and remain there, then it cannot do its job," said Oklu, the director of Mayo Clinics Minimally Invasive Therapeutics Laboratory.

Current treatment involves ablation, which involves heating or cooling the tumor or infusing radioactive particles into the arteries of the tumor to destroy the cancer cells and keep patients within the criteria for a transplant.

"You could do a microwave ablation and basically burn the tumor, but that is often not an option if the tumor is close to the heart or other important structures. And sometimes it is hard to find the blood supply of the tumor to infuse the radioactive particles," said Oklu.

The research team developed an ionic liquid essentially salt in a liquid state as an alternative way to deliver drugs into tumors through an ultrasound-guided needle injection. Once injected, the ionic liquid deposited the chemotherapy drugs uniformly, killing the cancer cells as the liquid engulfed the tumors.

Mitragotri and his lab have been pioneering the use of ionic liquids for all kinds of treatment applications, including as a way to deliver insulin by skin patches and pills, as nanoparticle coatings for targeted delivery, as vaccine adjuvants, and as a way to deliver therapeutics to treat psoriasis.

Ionic liquids are an exceptionally versatile group of materials, said Mitragotri. In our lab, we have already demonstrated that they have the ability to overcome a variety of biological barriers within the body for delivering drugs. In this study, we demonstrate a novel application of ionic liquids to deliver chemotherapeutic drugs in the liver tumor.

The researchers reported this approach was successful in preclinical studies using freshly resected human tumors in the lab and liver tumors in animal models. In addition, the authors reported that the chemotherapy remained in the targeted zone for the length of the 28-day trial.

Whereas drugs often wash away quickly from direct injection into tumors or from standard IV delivery of chemotherapy through the veins of the arm, the ionic liquid, which the authors call a "locally active agent for tumor treatment and eradication," or LATTE, also encouraged immune cell infiltration in the microenvironment of the tumor. This may play a role in achieving immunotherapy in solid tumors. The researchers say this could solve current challenges, especially in hepatocellular carcinoma the most common form of liver cancer where liver transplant can be curative.

The authors suggest that LATTE may work via diverse methods, and future studies are planned to expand on these preclinical findings. Future efforts might examine additional chemotherapy drugs, effects of immunotherapy agents and effects on overall survival, and involve a detailed analysis of local and body-wide immune implications of this experimental intervention.

This has been a very exciting collaboration, said Mitrigotri. Our lab focuses on chemistry, material science and engineering aspects of ionic liquids. This collaborative study with interventional radiologist Dr. Oklus lab at Mayo Clinic has enabled us to demonstrate a novel application of these amazing materials.

In addition to Oklu, Mayo Clinic authors include lead author Hassan Albadawi, Zefu Zhang, Izzet Altun, Jingjie Hu, and Leila Jamal. In addition to Mitragotri, authors from Harvard University are Kelly Ibsen, and Eden Tanner.

This study was funded by the National Institutes of Health.

Read this article:
Ionic liquid formulation can uniformly deliver chemotherapy to tumors while destroying cancerous tissue in preclinical studies | Harvard John A....

Final Report will add the analysis of the impact of COVID-19 on this industry.

Introduction and Scope: Rhodiola Extract MarketHolistic research derivatives focusing on Rhodiola Extract Market is a high-grade professional overview of various market determinants and factors representing factors, challenges, trends, threats, and a holistic overview that determine the overall growth directive of the Rhodiola Extract market. Crucial understanding on the various elements and growth propellants of the aforementioned market has been scrutinized effectively by research experts.

About Rhodiola Extract Market Growth:

Request Free Sample Reportwith Complete TOC and Figures & Graphs@https://www.mraccuracyreports.com/report-sample/207865

Rhodiola Extract Market Segment by Manufacturers, this report covers: Martin Bauer Group, Parchem, The Green Labs LLC, Shaanxi Jintai Biological Engineering Co., Ltd, Hawk-bio, Nutra Green Biotechnology Co.,Ltd

Market Segment by Type covers: Powdered, Encapsulated

Market Segment by Applications can be divided into: Medicine, Cosmetics, Supplements, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Rhodiola Extract market.

Production, consumption, revenue, market share, and growth rate are the key targets forRhodiola Extract Market forecast from 2013 to 2026 (forecast) in these regions:

Benefits of buying the report:

You can buy the complete report@https://www.mraccuracyreports.com/checkout/207865

Some Major Table of Contents:

Chapter 1: Global Rhodiola Extract Market Report 2020 Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.Chapter 2: Global Rhodiola Extract Market Report 2020 Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels, and Major Downstream Buyers.Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Global Rhodiola Extract Market Report 2020.Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Global Rhodiola Extract Market Report 2020.Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Global Rhodiola Extract Market Report 2020 by Regions.Chapter 6: Global Rhodiola Extract Market Report 2020 Production, Consumption, Export, and Import by Regions.Chapter 7: Global Rhodiola Extract Market Report 2020 Market Status and SWOT Analysis by Regions.Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Global Rhodiola Extract Market Report 2020.Chapter 9: Global Rhodiola Extract Market Report 2020 Market Analysis and Forecast by Type and Application.Chapter 10: Global Rhodiola Extract Market Report 2020 Market Analysis and Forecast by Regions.Chapter 11: Global Rhodiola Extract Market Report 2020 Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.Chapter 12: Global Rhodiola Extract Market Report 2020 Market Conclusion of the Whole Report.Continue

Get Exclusive Discount on this report @https://www.mraccuracyreports.com/check-discount/207865

About us:

MR Accuracy Reportsprovides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Contact Us:

Email:[emailprotected]

Website:www.mraccuracyreports.com

https://neighborwebsj.com/

See the original post here:
2021 Exclusive Insights on: Rhodiola Extract Market to Witness Robust Expansion throughout the Forecast Period| Martin Bauer Group, Parchem, The Green...

iCrowdNewswire Feb 12, 20213:30 PM ET

Chitin Market 2021-2027

A New Market Study, Titled Chitin Market Upcoming Trends, Growth Drivers and Challenges has been featured on fusionmarketresearch.

Description

This global study of theChitin marketoffers an overview of the existing market trends, drivers, restrictions, and metrics and also offers a viewpoint for important segments. The report also tracks product and services demand growth forecasts for the market. There is also to the study approach a detailed segmental review. A regional study of the globalChitin industryis also carried out in North America, Latin America, Asia-Pacific, Europe, and the Near East & Africa.The report mentions growth parameters in the regional markets along with major players dominating the regional growth.

Request a Sample Report @ https://www.fusionmarketresearch.com/sample_request/(COVID-19-Version)-Global-Chitin-Market/12603

Scopolamine is a medication used in the treatment of motion sickness and postoperative nausea and vomiting. Scopolamine is used to prevent nausea and vomiting caused by motion sickness or from anesthesia given during surgery.

The report offers detailed coverage of Chitin industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Chitin by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

First, this report covers the present status and the future prospects of the global Chitin market for 2015-2024.And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

At the same time, we classify Chitin according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.Finally, the report provides detailed profile and data information analysis of leading Chitin company.

Key CompaniesFMC CorpKitozymeKunpoong BioBIO21Heppe Medical ChitosanYaizu SuisankagakuGolden-ShellLushen BioengineeringAK BIOTECHZhejiang New Fuda Ocean BiotechWeifang Sea Source Biological ProductsQingdao Honghai Bio-techHaidebei Marine BioengineeringJiangsu Aoxin BiotechnologyJinhu Crust Product

Market Segment as follows:By RegionAsia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]North America[United States, Canada, Mexico]Middle East & Africa[GCC, North Africa, South Africa]South America[Brazil, Argentina, Columbia, Chile, Peru]

Market by TypeChitosan HClCarboxymethyl ChitosanChitosan Quaternary Ammonium SaltHydroxypropyl ChitosanChitosan OligosaccharideOthers

Market by ApplicationMedicalHealth FoodCosmeticsWater TreatmentOthersAsk Queries @ https://www.fusionmarketresearch.com/enquiry.php/(COVID-19-Version)-Global-Chitin-Market/12603 Table of Contents

Part 1 Market Overview1.1 Market Definition1.2 Market Development1.2.1 Current Situation1.2.2 Aspects of COVID-19 Impact1.3 By TypeTable Type of ChitinFigure Global Chitin Market Share by Type in 20191.4 By ApplicationTable Application of ChitinFigure Global Chitin Market Share by Application in 20191.5 By RegionFigure Global Chitin Market Share by Region in 2019Figure Asia Chitin Market Share by Region in 2019

Part 2 Key Companies2.1 FMC Corp2.1.1 Company ProfileTable FMC Corp Overview List2.1.2 Products & Services Overview2.1.3 Sales Data ListTable Chitin Business Operation of FMC Corp (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)2.2 Kitozyme2.3 Kunpoong Bio2.4 BIO212.5 Heppe Medical Chitosan2.6 Yaizu Suisankagaku2.7 Golden-Shell2.8 Lushen Bioengineering2.9 AK BIOTECH2.10 Zhejiang New Fuda Ocean Biotech2.11 Weifang Sea Source Biological Products2.12 Qingdao Honghai Bio-tech2.13 Haidebei Marine Bioengineering2.14 Jiangsu Aoxin Biotechnology2.15 Jinhu Crust Product

Part 3 Global Market Status and Future Forecast3.1 Global Market by RegionTable Global Chitin Market by Region, 2015-2019 (Million USD)Figure Global Chitin Market Share by Region in 2019 (Million USD)Table Global Chitin Market by Region, 2015-2019 (Volume)Figure Global Chitin Market Share by Region in 2019 (Volume)Table Price List by Region, 2015-20193.2 Global Market by CompanyTable Global Chitin Market by Company, 2015-2019 (Million USD)Figure Global Chitin Market Share by Company in 2019 (Million USD)Table Global Chitin Market by Company, 2015-2019 (Volume)Figure Global Chitin Market Share by Company in 2019 (Volume)Table Price List by Company, 2015-20193.3 Global Market by TypeTable Global Chitin Market by Type, 2015-2019 (Million USD)Figure Global Chitin Market Share by Type in 2019 (Million USD)Table Global Chitin Market by Type, 2015-2019 (Volume)Figure Global Chitin Market Share by Type in 2019 (Volume)Table Price List by Type, 2015-20193.4 Global Market by ApplicationTable Global Chitin Market by Application, 2015-2019 (Million USD)Figure Global Chitin Market Share by Application in 2019 (Million USD)Table Global Chitin Market by Application, 2015-2019 (Volume)Figure Global Chitin Market Share by Application in 2019 (Volume)Table Price List by Application, 2015-20193.5 Global Market by ForecastFigure Global Chitin Market Forecast, 2020-2025 (Million USD)Figure Global Chitin Market Forecast, 2020-2025 (Volume)ContinueABOUT US :

Fusion Market Research is one of the largest collections of market research reports from numerous publishers. We have a team of industry specialists providing unbiased insights on reports to best meet the requirements of our clients. We offer a comprehensive collection of competitive market research reports from a number of global leaders across industry segments.

[emailprotected]PH : +(210) 775-2636

Keywords:Chitin, Chitin Industry, Chitin Market Trends, Chitin Industry Trends, Chitin Market Growth, Chitin Market Size, Chitin Manufacturer, Global Chitin Industry, Global Chitin Market Trends, Chitin Growth, Global Chitin Market Share, Chitin Industry Analysis, Chitin Industry Forecast, Chitin Manufacturer, Chitin Manufacturers, Chitin Market, Chitin Market Forecast, Chitin Market Analysis, Chitin Market Parameters, Chitin Market Segmentation, Chitin Market Share, Chitin Market Trend, Chitin Prospectus, Chitin Research Report, Chitin Segmentation, Global Chitin Market Size, Global Chitin Survey

Here is the original post:
Global Chitin 2021 Industry, Market Growth, Analysis, Trend and Forecast to 2027 Wall Street Call - Reported Times

The report titled Algae Oil Market By Grade (Fuel Grade, Food Grade, and Feed Grade), By Application (Food & Beverage, Biofuel, Dietary Supplements, and Animal Feed), And By Region Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 2026 utilizing diverse methodologies aims to examineand put forth in-depth and accurate data regarding the globalAlgae Oil Market.To begin with, the report comprises the major players actively participating and competing within theAlgae Oil Market; it entails several companies, manufacturers, suppliers, organizations, and so on. Thus, the report will assist in understanding the initiatives and approaches implemented by these players to create and reinforce their market presence.The report is segregated into different well-defined sections to provide the reader with an easy and understandable informational document. Further, each section is elaborated with all the required data to gain knowledge about the market before entering it or reinforcing their current foothold. The report is divided into:

Request Free Sample Report of Algae Oil Market Report @https://www.zionmarketresearch.com/sample/algae-oil-market

Along with the market overview, the report comprises Porters Five Forces analysis elucidating the five forces: explicitly suppliers bargaining power, degree of competition, buyers bargaining power, and threat of substitutes in the globalAlgae Oil Market.In addition, theAlgae Oil Marketreport also entails the number of participants, like intermediaries, system integrators, and end-users existing in the globalAlgae Oil Marketwhile putting forth the competitive landscape to get a clearer view of the markets growth statistics and dynamics.

The key major market players include:Lonza Group Ltd.; Royal DSM; Runke Biological Company; Cargill Alking Bioengineering; Rishon International Group; Cellana Inc.; and Hubei Fuxing Biotechnology.

The report encompasses the leading manufacturers along with their respective share in the global market in terms of revenue. Moreover, it mentions their tacticalsteps in the last few years, leadership changes, and product innovationinvestmentsto help in making well-informed decision and also to stay at forefront in the competition.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/algae-oil-market

Moving to the growth drivers and restraints section, one will be presented with all factors that are directly or indirectly aiding the growth of the globalAlgae Oil Market. To get acquainted with the markets growth statistics, it is essential to assess the several drivers of the market. In addition, the report also puts forth the existing trends along with new and possible growth opportunities in the global market.Moreover, the report includes the factors that can possibly hinder the growth of the market. Understanding these factors is similarlycrucial as they aid in comprehending the markets weaknesses.

The segmentation of the globalAlgae Oil Marketsegregates the market based on different aspects such as Type, Application, end use industry and region. Further, each segment is elaborated providing all the vital details along with growth analysis for the forecast period. The report also divides the market by region into North America, Europe, AsiaPacific, the Middle East & Africa, and Latin America. The regional analysis covers the volume and revenue assessment of every region along with their respective countries. In addition, the report also entails various market aspects such as import & export, supply chain value, market share, sales, volume, and so on.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/algae-oil-market

Primary and secondary approaches are being used by the analysts and researchers to compile thesedata. Thus, thisAlgae Oil Marketis intended at directing the readers to a better, apprehensive, and clearer factsand data of the globalAlgae Oil Market..

The latestAlgae Oil Marketreport is crafted along with the ongoing COVID-19-stimulated pandemic condition that has severely influenced the market growth on global as well as regional extents. It presents thorough market study on the basis of the post-COVID-19 and existing market scenario. Also, it includes the likely future impacts of the outbreak on the globalAlgae Oil Market

Research objectives

Frequently Asked Questions

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research244 Fifth Avenue, Suite N202New York, 10001, United StatesTel: +49-322 210 92714USA/Canada Toll-Free No.1-855-465-4651Email:sales@zionmarketresearch.comWebsite:https://www.zionmarketresearch.com

Read this article:
Latest Report on Algae Oil Market to Drive Amazing Growth by 2026 | Lonza Group Ltd.; Royal DSM; Runke Biological Company; Cargill Alking...

It was Christmas Eve in 2015. The seasonal festive vibe was blocked out from the science lab in UC Berkley, California, where bioengineering doctoral candidate Lee Gun-woo, then 27, was immersed in his research.

Lees heart quickened as he watched the results of his experiment unravel before his eyes. A polymer nanoparticle traveled straight to his intended target genome in a test rat and changed its DNA.

A jolt ran down his spine. This could make CRISPR DNA scissors work in the human body. It could be a game changer in delivering drugs to tackle genetically caused illnesses, he thought.

Lee dialed up his friend and fellow scientist Park Hyo-min.

Hyeong, lets start a company, Lee said.

The conception

The story of Lee Gun-woo, 33, and Park Hyo-min, 41, is truly an American Dream come true.

The duo co-founded the gene therapy company GenEdit in May 2016 with Lee as the chief executive officer leading research and Park as the chief technology officer responsible for validation of development.

What GenEdit does is step up the game for the groundbreaking DNA scissors technology called CRISPR.

The technology snips parts of the human DNA to remove or insert new genetic material. The Nobel Prize for Chemistry in 2020 went to scientists Emmanuelle Charpentier and Jennifer Doudna for their contribution to its discovery.

Lee and Park are not strangers to the leading CRISPR researcher Doudna, who is a professor at their alma mater UC Berkley.

Doudnas name is listed as a contributor to Lee and Parks co-authored article published in Nature in 2017, titled Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Lee, Park and scientist Michael Convoy have equal stakes in the piece as main authors, according to the science journal.

CRISPR gene editing is a two-part system comprising a customizable guide RNA and a protein called Cas9.

The guide RNA directs Cas9 to any desired segment of DNA for editing. The Cas9 enzyme then cuts the DNA at that precise location, allowing for genes to be turned on or off or for the removal or insertion of DNA. But editing the DNA of cells in a petri dish -- or even curing a mouse of a disease -- is one thing; making the hot new technology work in humans is a whole other challenge. Sneaking the gene-editing complex into human cells is no easy task, according to American Chemical Societys Chemical & Engineering News introductory article dated 2017.

This is where GenEdit steps in.

Born out of UC Berkleys laboratory, GenEdits polymer nanoparticle delivery technology can make the Cas9 travel to the desired location in human body. This innovative concept has attracted global angel investors such as the likes of Sequoia Capital, Bow Capital, Data Collective Bio and SK Holdings. The Series Seed financing round raised a total of $8.5 million, led by DCVC Bio and SK Holdings.

Before he knew it, Lee was named in Forbes top 30 entrepreneurs under the age of 30 in 2018.

5th anniversary

Now in its fifth year, GenEdit aspires for the future where all hereditary illness can be cured with gene therapies.

There are countless ailments that are passed down the blood line and GenEdit is studying DNA markers for non-viral polymers that will match them.

Speaking to The Korea Herald in a video interview, CTO Park Hyo-min said that GenEdit will soon decide on the first target disease within 2021.

Were not definitive at this point, but there is a good chance we will narrow down our focus to central nervous system diseases, for which we have been able to amass a volume of promising data, Park said.

It is not with absolute certainty I say this, but we may be able to deliver a novel drug for a rare CNS disease within the next six to seven years, said Park, if authorities fast-track their approval for orphan drugs for rare diseases.

Park declined to say if Alzheimers Disease or dementia were research subjects.

We are aware that companies who tackle AD receive tremendous attention from investors. However, conditions like AD or dementia do not have a clear genetic cause, Park said, underlining that GenEdits target indications are only those with high correlation with genetic roots.

Other than CNS indications, the company is also perusing therapies for liver and immune cell diseases.

The liver has comparatively low hurdle for drug delivery mechanisms, Park said, Precisely for that reason there is much competition in the area of liver treatments, but we may still consider to throw our gloves in.

Apart from their main target pipeline, for which GenEdit intends to see through to drug commercialization, the company is open to strategically licensing out other findings, Park said.

When asked what motivates these researches, and what does it feel like to be a young, celebrated scientist, CEO Lee Gun-woo -- who is eight years younger than co-founder Park -- remained modest.

Through this winding long process of life, I dream of serving the society in any way I can. To be able to serve, I believe its imperative to broaden my capabilities, Lee said.

I had the opportunity to listen to astronaut Jonny Kims webinar. He spoke of Martin Luther King and the life of service, that everyone is capable of greatness through the act of giving, Lee said. One of my dreams is to use science to benefit more patients, and I am profoundly grateful that I am on that path.

The young co-founders of GenEdit had not foreseen that they would be leading a gene therapy company in the US when they first set foot on US soil in 2011.

Lee had come straight after his bachelors degree in bioengineering at Korea Advanced Institute of Science and Technology in Daejeon, and Park had come after completing a masters in food science at Korea University in Seoul.

Lee had spent most of his life growing up in his home city of Daegu, while Park had lived in Seoul.

I would like to tell scientists in Korea that they must create reasons to come out to the US. Korea has great science, but one cant deny that its here in the US where all the breakthrough innovations happen, said Park.

If in Korea, every academic novelty would have to be indirectly studied. Here, everything becomes a raw, immediate experience. We get to be in the heart of the research leading scientific progress, shoulder-to-shoulder with Nobel laureates, Park said.

Being in southern California, we are adjacent to companies like Genentech. Remember the time when the only drugs available were swallowable tablets? Genentech is the company that pioneered the protein-based drug shots that revolutionized cancer therapies. We aspire to be the next Genentech in the realm of gene therapies, Lee said.

His source of joy is his parents who send him support from Daegu. Although there are limitations to their comprehension of the intricate science of Lees work, news of their son always fills them with pride, Lee said. Due to the COVID-19 pandemic, Lee has not been able to pay them visits as of late.

As for Park, he is most thankful to Lee and his wife for being a spiritual buttress. As a father of four, with his eldest now 12 years old, Park says he is especially thankful to Lee for clocking in more hours at work, and to his wife for her sacrificial love.

What binds Lee and Park together as partners is the deep trust and camaraderie that has built up in the decade they have known each other. The five years in school and five years in business have united them as near-family and made them an inseparable team.

As of February, GenEdit had 17 full-time employees, of whom 14 were researchers. By the end of the year, GenEdit plans to boost the headcount to 27 full-time workers. Lee and Park said that they have built a culture where it is OK to make mistakes and keep matters transparent. Anyone who wants to try some cool science and do fun researches is welcome to join this science-focused team, they said.

By Lim Jeong-yeo (kaylalim@heraldcorp.com)

Go here to see the original:
[Herald Interview] GenEdit to hone in on nervous system disorders in 2021 blueprint - The Korea Herald

Bioinformatics is a branch of science that uses technology to collect vital information pertaining to the bioengineering, biology, and biotechnology domain to present a logical analysis. To perform the analysis it uses various software tools, which are specifically designed for generating a biology analysis termed as bioinformatics software. Today, these tools are being used for creating predictive modeling and expression analysis of various genes and phenotypes. Adoption of bioinformatics software tools has significantly reduced the technical burden, introduced accuracy, and enabled efficiency in the scientific research is conducted.

The research report by Transparency Market Research has been compiled with deliberation and meticulous assessment of various factors. With primary and secondary research methodologies used to compile the overall report, the publication offers a thorough understanding of the globalbioinformatics software for predictive modeling and expression analysis. The report includes comments and recommendations by expert market leaders, which are aimed at helping the readers make well-informed business decisions.

Request for a sample:

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2394

Global Bioinformatics Software for Predictive Modeling and Expression Analysis Market: Trends and Drivers

The sudden drop in the prices of gene sequencing and the subsequent rise in the demand for gene expression and predictive modeling has led to the emergence of bioinformatics software for predictive modeling and expression analysis. The market is also thriving due to the emerging trend of outsourcing bioinformatics services and the superb technological advancements in the corresponding field. The entry of several new players who are taking up contracts of delivering bioinformatics services along with offering value added services has given the global market tremendous boost. The growth of the pharmaceutical industry and the evolution of healthcare industry have been the very turning points for the global bioinformatics software for predictive modeling and expression analysis.

Global Bioinformatics Software for Predictive Modeling and Expression Analysis Market: Regional Outlook

In terms of geography, the global market is segmented into North America, Asia Pacific, Rest of the World, and Europe. Currently, North America holds a leading share in the bioinformatics software for predictive modeling and expression analysis market. The region is expected to assert its dominance in the coming years due to the well-established healthcare infrastructure, higher acceptance of technological advancements, and increasing investments in the development of software tools. Furthermore, increasing awareness amongst healthcare professionals about advantages of deploying bioinformatics software for predictive modeling and expression analysis is also expected to fuel the rise of the regional market in the near future. Europe trails this lead quite closely for similar reasons and is expected to remain a steady contributor to the rising revenue of the global market in the coming years.

Ask for brochure:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2394

On the other hand, the fast-paced growth of the medical sector in Asia Pacific is also expected to offer several lucrative opportunities to Asia-Pacific bioinformatics software for predictive modeling and expression analysis market. The emergence of medical tourism in developing countries such as China, India, and Japan are likely to utilize these methods in areas of gene expression, drug discovery, and determination of phenotypic information. Furthermore, increasing investments by the governments to improve the healthcare sector is also expected to fuel the Asia Pacific bioinformatics software for predictive modeling and expression analysis.

Read TMR Research Methodology at:https://www.transparencymarketresearch.com/methodology.html

Key Companies Mentioned in the Report are:

The prominent players operating in the global bioinformatics software for predictive modeling and expression analysis market are SmartGene Services SARL, Accelrys, Inc., Affymetrix, Inc., Agilent Technologies Inc., Biobase GmbH, Cartagenia N.V., CLC bio A/S, DNASTAR, Inc., PerkinElmer, Inc., GenoLogics Life Sciences Software Inc., Illumina, Inc., Genedata AG, Genomatix Software GmbH and Molecular Networks GmbH.

Read Our Latest Press Release:

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions tobusiness leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. Fororganizationsthat require specific butcomprehensiveinformation we offer customized solutions through ad-hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

Contact

Transparency Market Research State Tower,

90 State Street,

Suite 700,

Albany NY 12207

United States

USA Canada Toll Free: 866-552-3453

Email:sales@transparencymarketresearch.com

Website:https://www.transparencymarketresearch.com

See more here:
Bioinformatics Software for Predictive Modeling and Expression Analysis Market 2021 : Growth And Future Prospects Analyzed KSU | The Sentinel...

Superspreading events have distinguished the COVID-19 pandemic from the early outbreak of the disease. Now, research from Harvard University, Tulane University, MIT and Massachusetts General Hospital finds that a critical factor in these and other transmission events is the propensity of certain individuals to exhale large numbers of small respiratory droplets. The researchers found that age, obesity and COVID-19 infection all correlate with a propensity to breathe out more respiratory droplets.

Understanding the source and variance of respiratory droplet generation may lead to effective approaches to reducing COVID-19 infection and transmission.

The study was published yesterday in the Proceedings of the National Academy of Sciences.

Respiratory droplet generation in the airways varies between people depending on their phenotype, said David Edwards, Associate in Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences and co-author of the study. While our results show that the young and healthy tend to generate far fewer droplets than the older and less healthy, they also show, in combination with the results from nonhuman primates, that any of us, when infected by COVID-19, may be at risk of producing a large number of respiratory droplets. This is an important finding in that the majority of these droplets are smaller than a single micron, meaning they can carry infection deep into our lungs and propagate infection very far in poorly circulated indoor settings.

Using data from an observational study of 194 healthy people, ages 19 to 66, and an experimental study of nonhuman primates with COVID-19, researchers found that exhaled aerosol particles vary greatly between subjects. Those who were older with higher body mass indexes (BMI) and increasing degree of COVID-19 infection had three times the number of exhaled respiratory droplets as others in the study group.

The researchers found that 18 percent of human subjects accounted for 80 percent of the exhaled particles of the group, reflecting a distribution of exhaled aerosol particles analogous to a classical 20:80 super-spreader distribution of airborne infection. The findings suggest that quantitative assessment and control of exhaled aerosol may be critical to slowing the airborne spread of COVID-19 in the absence of an effective and widely disseminated vaccine.

Our nonhuman primate studies suggest that within a few days of infection by SARS-CoV-2 aerosol, exhaled aerosol increases with the rise of viral replication in the airways, reaching a peak within about a week from first infection and then diminishing in magnitude as the infection is cleared to return to baseline within two weeks post infection, said co-author Chad Roy, Professor of Microbiology and Immunology at Tulane School of Medicine and a core scientist at the Tulane National Primate Research Center at Tulane University. We observed these same phenomena with TB-infected nonhuman primates. It seems likely that viral and bacterial infection of the airway weaken airway mucus in similar ways and promote airborne movement of infection with risks to ourselves and those around us.

The authors argue that management of COVID-19 through the restoration of airway lining mucus barrier function, and, monitoring of exhaled aerosol numbers might be important strategies in the control of transmission and infection of COVID-19, and other respiratory infectious diseases, including TB and influenza.

The research was co-authored by Dennis Ausiello, of Massachusetts General Hospital and Harvard Medical School; Jonathan Salzman and Tom Devlin, of Sensory Cloud; Robert Langer, of the Massachusetts Institute of Technology; and Brandon J. Beddingfield, Alyssa C. Fears, Lara A. Doyle-Meyers, Rachel K. Redmann, Stephanie Z. Killeen and Nicholas J. Maness, of Tulane National Primate Research Center .

It was supported in part by National Institute of Allergy and Infectious Disease (Grant # HHSN272201700033I), the National Institutes of Health (Grant # OD01110) and the Bill & Melinda Gates Foundation

Read the original:
Exhaled respiratory droplets increase with the onset of COVID-19 infection and with aging and obesity | Harvard John A. Paulson School of Engineering...

ByEmily Steele, Illinois Extension, Media Communications Coordinator| Special to the McDonough County Voice

URBANA, Ill. Spring is characterized by a fury of activity on farms. In the rush to get crops in the ground, farmers may not have safety and health as a priority.

Learn how to prevent common farm injuries and illness during this critical time at a free online webinar by University of Illinois Extension and AgrAbility. Preparing for a Safe Planting Season will run from noon to 1 p.m. CT Feb. 18 online via Zoom. Register online atgo.illinois.edu/AgrSafePlanting. Those who cannot attend live can still sign up to receive access to the recorded webinar.

In Illinois, we often see an uptick in agricultural-related injuries in the spring, saysJosie Rudolphi, Illinois Extensionspecialist. And COVID-19 will again present additional health and safety challenges to farmers.

Extension andIllinois AgrAbilityare joining together to provide practical tips and seasonal reminders appropriate for large and small-scale producers and farm families. Rudolphi will be joined bySalah Issafrom theCollege of Agricultural and Biological Engineering.

Illinois Extension provides equal opportunities in programs and employment. If you need a reasonable accommodation to participate, contact Josie Rudolphi atjosier@illinois.edu. Early requests are strongly encouraged to allow sufficient time for meeting access needs.

Source: Josie M. Rudolphi,Illinois Extension Specialist, Assistant Professor, College of Agricultural and Biological Engineering

About Illinois Extension: Illinois Extension leads public outreach for University of Illinois by translating research into action plans that allow Illinois families, businesses, and community leaders to solve problems, make informed decisions, and adapt to changes and opportunities.

Original post:
Stay safe on the farm this planting season - McDonough Voice

Four Caltech professors, along with one principal staff member from the Jet Propulsion Laboratory, have been named as fellows of the American Association for the Advancement of Science (AAAS). In total, 14 Caltech alumni were named as fellows this year.

AAAS Fellows are a distinguished cadre of scientists, engineers, and innovators who have been recognized for their achievements across disciplines, from research, teaching, and technology, to administration in academia, industry, and government, to excellence in communicating and interpreting science to the public. The 2022 class of AAAS Fellows includes 564 scientists, engineers, and innovators spanning 24 scientific disciplines.

William G. Dunphy

Grace C. Steele Professor of Biology

"For elucidating the complex network of enzymes that commit a cell to mitosiscritical information for understanding DNA replication and preservation of genomic integrity."

Dunphy received his PhD from Stanford in 1985. He joined the Caltech faculty in 1989.

Viviana Gradinaru (BS '05)

Professor of neuroscience and biological engineering; director, Center for Molecular and Cellular Neuroscience

"For extraordinary achievements in bioengineering and neuroscience, including development and sharing of multiple novel tools to enable functional and anatomical access to the vertebrate nervous system."

Gradinaru received her PhD from Stanford in 2010. She joined the Caltech faculty in 2012.

Stephen Mayo (PhD '87)

Bren Professor of Biology and Chemistry; Merkin Institute Professor

"For distinguished contributions to the field of protein design technology."

Mayo received his PhD from Caltech in 1987. He joined the faculty in 1992.

Carol Polanskey (MS '84, PhD '89)

Planetary scientist, JPL

"For distinguished contributions to the field of planetary science, especially the structure and dynamics of asteroids and other small planetary bodies as well as exemplary leadership and development of space science missions."

Polanskey received her PhD from Caltech in 1989.

Paul O. Wennberg

R. Stanton Avery Professor of Atmospheric Chemistry and Environmental Science and Engineering; executive officer for environmental science and engineering; director, Ronald and Maxine Linde Center for Global Environmental Science

"For major scientific advances in atmospheric chemistry."

Wennberg received his PhD from Harvard in 1994. He joined the Caltech faculty in 1998.

In addition to Gradinaru, Mayo, and Polanskey, 11 other Caltech alumni were elected as AAAS fellows this year: Andrea M. Armani (MS '03, PhD '07), Pratim Biswas (PhD '85), Eric Christian (MS '85, PhD '89), Brian C. Freeman (BS '79), Stephen Craig Hadler (BS, '69), Thomas Mark McCleskey (PhD '94), Charles Ofria (PhD '99), Padhraic Smyth (MS '85, PhD '88), Lynmarie K. Thompson (BS '83), Paula I. Watnick (PhD '89), and Yannis Yortsos (MS '74, PhD '79).

See more here:
Caltech Faculty Members and JPL Researcher Named as AAAS Fellows - Caltech

Global ?-Polylysine Market from 2021 to 2027 is the professional market research study by MRInsights.biz covering growth prospects and market development potential. The report offers the overall industry structure, explaining the market summary, specification, product definition, and objectives.It also has separate chapters that include the regional studies to get a picture of the markets with future opportunities followed by the estimated yearly growth during the survey period from 2021 to 2027.

The document presents the business customers with an in-depth review of the global ?-Polylysine market, giving an evaluation of the market trends, market size, market value, and market growth over the forecast duration on a compound in addition to on a yearly basis. The study clarifies the market situation and forecast subtleties of the essential zones, with the logical presentation of preeminent producers, product types, and end-client associations.

DOWNLOAD FREE SAMPLE REPORT: https://www.mrinsights.biz/report-detail/241151/request-sample

A global attitude on substantial regions is also protected in the document, particularly

Product offers, revenue analysis, manufacturing capabilities, gross margins, and several different critical factors that affect a companys profitability in the market also are included. Market segment by type, the product is divided into

The document enumerates information approximately business phase of the market:

The evaluation of the following companies has been provided in the report:

ACCESS FULL REPORT: https://www.mrinsights.biz/report/global-polylysine-market-growth-2021-2026-241151.html

An extensive evaluation based on the market segment might be beneficial to enhance the commercial enterprise development. This report also gives SWOT evaluation, funding feasibility evaluation, and funding go again evaluation.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@mrinsights.bizWeb: http://www.mrinsights.biz

See more here:
Global ?-Polylysine Market 2021 COVID-19 Impact Analysis and Top Companies as Jnc-Corp, Siveele, Handary, Zhejiang Silver Elephant Bioengineering The...